GSK plc

GSK plc researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat diseases globally, including in the United Kingdom and the United States. The company operates through two segments: Commercial Operations and Total R&D. Its specialty medicines address conditions such as HIV, respiratory eosinophil-driven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer, encompassing oncology, respiratory/immunology, inflammation, and inhaled medicines. GSK offers a range of vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. General medicines are provided for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. The company also focuses on discovering, developing, and commercializing oral small molecule therapies for oncology and inflammatory diseases. GSK has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases and a strategic alliance with AN2 Therapeutics, Inc. for new TB therapies. Founded in 1715, GSK plc, formerly GlaxoSmithKline plc until May 2022, is headquartered in London, United Kingdom.